{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T14:45:11Z","timestamp":1760453111446},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Stroke is frequently a disabling and even life-threatening condition that has an ischaemic cause in most cases. Transient ischaemic attack (TIA) is a lower risk condition that still exposes to the risk of future major cardiovascular events. The causes of stroke can be classified as cardioembolic disease, large vessel disease, small vessel disease, undetermined, or others. Cardioembolic disease and atherothrombosis of large arteries are the most common underlying processes of ischaemic stroke and TIA. Therefore, antithrombotic therapy is a central strategy in the pharmacological management of these patients. However, because antithrombotic therapy provides ischaemic protection at the price of increased bleeding, defining the fine balance between efficacy and safety is a clinical challenge. Numerous trials have recently defined the current indications to the use of anticoagulant and antiplatelet therapy in patients with various subtypes of ischaemic stroke or TIA. In this review, we provide an updated appraisal of the currently available evidence on the use of various oral antithrombotic agents for prevention of recurrent events after an ischaemic stroke or TIA.<\/jats:p>","DOI":"10.1093\/ehjcvp\/pvab062","type":"journal-article","created":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T19:12:26Z","timestamp":1628277146000},"page":"383-391","source":"Crossref","is-referenced-by-count":5,"title":["Oral antithrombotic therapy for the prevention of recurrent cerebrovascular events"],"prefix":"10.1093","volume":"8","author":[{"given":"Davide","family":"Capodanno","sequence":"first","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero Universitaria Policlinico \u201cG. Rodolico-San Marco\u201d, University of Catania , Catania , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominick J","family":"Angiolillo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Florida College of Medicine , 655 West 8th Street, Jacksonville, FL 32209 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,8,10]]},"reference":[{"key":"2022060809381919600_bib1","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1161\/CIR.0000000000000950","article-title":"Heart disease and stroke statistics\u20142021 update","volume":"143","author":"Virani","year":"2021","journal-title":"Circulation"},{"key":"2022060809381919600_bib2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nrcardio.2016.111","article-title":"Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease","volume":"13","author":"Capodanno","year":"2016","journal-title":"Nat Rev Cardiol"},{"key":"2022060809381919600_bib3","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1001\/archinte.167.22.2417","article-title":"Early risk of stroke after transient ischemic attack","volume":"167","author":"Wu","year":"2007","journal-title":"Arch Intern Med"},{"key":"2022060809381919600_bib4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1603060","article-title":"Ticagrelor versus aspirin in acute stroke or transient ischemic attack","volume":"375","author":"Johnston","year":"2016","journal-title":"N Engl J Med"},{"key":"2022060809381919600_bib5","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1161\/STR.0000000000000211","article-title":"Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"50","author":"Powers","year":"2019","journal-title":"Stroke"},{"key":"2022060809381919600_bib6","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1161\/STR.0000000000000069","article-title":"Guidelines for the management of spontaneous intracerebral hemorrhage","volume":"46","author":"Hemphill","year":"2015","journal-title":"Stroke"},{"key":"2022060809381919600_bib7","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2022060809381919600_bib8","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1161\/STROKEAHA.113.675140","article-title":"Adelaide Stroke Incidence Study","volume":"44","author":"Leyden","year":"2013","journal-title":"Stroke"},{"key":"2022060809381919600_bib9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jacc.2019.11.024","article-title":"Embolic stroke of undetermined source","volume":"75","author":"Ntaios","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022060809381919600_bib10","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/0140-6736(93)92358-Z","article-title":"Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group","volume":"342","year":"1993","journal-title":"Lancet"},{"key":"2022060809381919600_bib11","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S1474-4422(10)70274-X","article-title":"Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial","volume":"9","author":"Diener","year":"2010","journal-title":"Lancet Neurol"},{"key":"2022060809381919600_bib12","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S1474-4422(12)70042-X","article-title":"Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF","volume":"11","author":"Hankey","year":"2012","journal-title":"Lancet Neurol"},{"key":"2022060809381919600_bib13","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S1474-4422(12)70092-3","article-title":"Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial","volume":"11","author":"Easton","year":"2012","journal-title":"Lancet Neurol"},{"key":"2022060809381919600_bib14","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1161\/STROKEAHA.116.013540","article-title":"Outcomes with edoxaban versus warfarin in patients with previous cerebrovascular events","volume":"47","author":"Rost","year":"2016","journal-title":"Stroke"},{"key":"2022060809381919600_bib15","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1161\/CIRCULATIONAHA.120.049768","article-title":"Stroke prevention in atrial fibrillation","volume":"142","author":"Katsanos","year":"2020","journal-title":"Circulation"},{"key":"2022060809381919600_bib16","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1802686","article-title":"Rivaroxaban for stroke prevention after embolic stroke of undetermined source","volume":"378","author":"Hart","year":"2018","journal-title":"N Engl J Med"},{"key":"2022060809381919600_bib17","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1056\/NEJMoa1813959","article-title":"Dabigatran for prevention of stroke after embolic stroke of undetermined source","volume":"380","author":"Diener","year":"2019","journal-title":"N Engl J Med"},{"key":"2022060809381919600_bib18","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1161\/01.STR.20.7.864","article-title":"Measurements of acute cerebral infarction: a clinical examination scale","volume":"20","author":"Brott","year":"1989","journal-title":"Stroke"},{"key":"2022060809381919600_bib19","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(07)60150-0","article-title":"Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack","volume":"369","author":"Johnston","year":"2007","journal-title":"Lancet"},{"key":"2022060809381919600_bib20","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(97)04011-7","article-title":"The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"2022060809381919600_bib21","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0140-6736(97)04010-5","article-title":"CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"2022060809381919600_bib22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(16)30468-8","article-title":"Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials","volume":"388","author":"Rothwell","year":"2016","journal-title":"Lancet"},{"key":"2022060809381919600_bib23","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","author":"CAPRIE Steering Committee","year":"1996","journal-title":"Lancet"},{"key":"2022060809381919600_bib24","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1161\/01.STR.0000110221.54366.49","article-title":"Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events","volume":"35","author":"Ringleb","year":"2004","journal-title":"Stroke"},{"key":"2022060809381919600_bib25","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S1474-4422(18)30449-6","article-title":"Comparison of prasugrel and clopidogrel in patients with non-cardioembolic ischaemic stroke: a phase 3, randomised, non-inferiority trial (PRASTRO-I)","volume":"18","author":"Ogawa","year":"2019","journal-title":"Lancet Neurol"},{"key":"2022060809381919600_bib26","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000506825","article-title":"Safety and efficacy of prasugrel in elderly\/low body weight Japanese patients with ischemic stroke: randomized PRASTRO-II","volume":"49","author":"Kitagawa","year":"2020","journal-title":"Cerebrovasc Dis"},{"key":"2022060809381919600_bib27","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1474-4422(17)30038-8","article-title":"Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial","volume":"16","author":"Amarenco","year":"2017","journal-title":"Lancet Neurol"},{"key":"2022060809381919600_bib28","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1161\/STROKEAHA.118.020553","article-title":"Efficacy and safety of ticagrelor in relation to aspirin use within the week before randomization in the SOCRATES trial","volume":"49","author":"Wong","year":"2018","journal-title":"Stroke"},{"key":"2022060809381919600_bib29","first-page":"1351","article-title":"Principal end-points. The ESPS Group","volume":"2","author":"The European Stroke Prevention Study (ESPS)","year":"1987","journal-title":"Lancet"},{"key":"2022060809381919600_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-510X(96)00308-5","article-title":"European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke","volume":"143","author":"Diener","year":"1996","journal-title":"J Neurol Sci"},{"key":"2022060809381919600_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001820","article-title":"Dipyridamole for preventing stroke and other vascular events in patients with vascular disease","author":"De Schryver","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"2022060809381919600_bib32","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1053\/jscd.2000.7216","article-title":"Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction","volume":"9","author":"Gotoh","year":"2000","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2022060809381919600_bib33","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1474-4422(10)70198-8","article-title":"Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial","volume":"9","author":"Shinohara","year":"2010","journal-title":"Lancet Neurol"},{"key":"2022060809381919600_bib34","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","article-title":"Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial","volume":"364","author":"Diener","year":"2004","journal-title":"Lancet"},{"key":"2022060809381919600_bib35","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"key":"2022060809381919600_bib36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1747-4949.2010.00535.x","article-title":"Effect of clopidogrel plus ASA vs. ASA early after TIA and ischaemic stroke: a substudy of the CHARISMA trial","volume":"6","author":"Hankey","year":"2011","journal-title":"Int J Stroke"},{"key":"2022060809381919600_bib37","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1161\/01.CIR.0000163561.90680.1C","article-title":"Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection","volume":"111","author":"Markus","year":"2005","journal-title":"Circulation"},{"key":"2022060809381919600_bib38","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S1474-4422(07)70250-8","article-title":"Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial","volume":"6","author":"Kennedy","year":"2007","journal-title":"Lancet Neurol"},{"key":"2022060809381919600_bib39","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1474-4422(10)70060-0","article-title":"Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial","volume":"9","author":"Wong","year":"2010","journal-title":"Lancet Neurol"},{"key":"2022060809381919600_bib40","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1215340","article-title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"2022060809381919600_bib41","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa1800410","article-title":"Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA","volume":"379","author":"Johnston","year":"2018","journal-title":"N Engl J Med"},{"key":"2022060809381919600_bib42","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","article-title":"Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention","volume":"12","author":"Sibbing","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"2022060809381919600_bib43","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/jama.2016.8662","article-title":"Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack","volume":"316","author":"Wang","year":"2016","journal-title":"JAMA"},{"key":"2022060809381919600_bib44","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/jamaneurol.2019.2531","article-title":"Outcomes associated with clopidogrel\u2013aspirin use in minor stroke or transient ischemic attack","volume":"76","author":"Pan","year":"2019","journal-title":"JAMA Neurol"},{"key":"2022060809381919600_bib45","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1916870","article-title":"Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA","volume":"383","author":"Johnston","year":"2020","journal-title":"N Engl J Med"},{"key":"2022060809381919600_bib46","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1161\/01.STR.0000149621.95215.ea","article-title":"Dipyridamole for preventing recurrent ischemic stroke and other vascular events","volume":"36","author":"Leonardi-Bee","year":"2005","journal-title":"Stroke"},{"key":"2022060809381919600_bib47","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(06)68734-5","article-title":"Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial","volume":"367","author":"ESPRIT Study Group","year":"2006","journal-title":"Lancet"},{"key":"2022060809381919600_bib48","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1136\/jnnp.2008.143875","article-title":"Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk","volume":"79","author":"Halkes","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2022060809381919600_bib49","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1056\/NEJMoa0805002","article-title":"Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke","volume":"359","author":"Sacco","year":"2008","journal-title":"N Engl J Med"},{"key":"2022060809381919600_bib50","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1474-4422(19)30148-6","article-title":"Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial","volume":"18","author":"Toyoda","year":"2019","journal-title":"Lancet Neurol"},{"key":"2022060809381919600_bib51","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S0140-6736(17)32849-0","article-title":"Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial","volume":"391","author":"Bath","year":"2018","journal-title":"Lancet"},{"key":"2022060809381919600_bib52","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1001\/jamaneurol.2020.2494","article-title":"New horizons in pharmacologic therapy for secondary stroke prevention","volume":"77","author":"Katsanos","year":"2020","journal-title":"JAMA Neurol"},{"key":"2022060809381919600_bib53","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41569-019-0314-y","article-title":"Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease","volume":"17","author":"Capodanno","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2022060809381919600_bib54","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European Guidelines on cardiovascular disease prevention in clinical practice","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"issue":"2","key":"2022060809381919600_bib55","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/2396987321992905","article-title":"European Stroke Organisation (ESO) guidelines on management of transient ischaemic attack","volume":"6","author":"Fonseca","year":"2021","journal-title":"Eur Stroke J"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvab062\/39890282\/pvab062.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/8\/4\/383\/43976750\/pvab062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/8\/4\/383\/43976750\/pvab062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T09:39:31Z","timestamp":1654681171000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/8\/4\/383\/6347345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,10]]},"references-count":55,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,8,10]]},"published-print":{"date-parts":[[2022,6,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvab062","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7]]},"published":{"date-parts":[[2021,8,10]]}}}